These findings further suggest that in situ sTrem2 administration may represent an effective approach to treating non‐resolving wounds in patients with diabetes, while emphasizing the essential roles that macrophage Trem2 plays in the regulation of dermal fibroblast activity. Here, TREM2 is linked to diabetes mellitus.